Applications of Flavopiridol in Industrial Manufacturing

As a c-GMP manufacturer, we provide flavopiridol as a specialty chemical raw material for critical pharmaceutical and biotechnology applications. Our expertise enables precise integration of flavopiridol in regulated industrial processes where compliance, quality consistency, and traceability are essential. Below are major downstream application scenarios, each with details on regulation, usage ratios, process steps, and resultant finished goods.

1. Anticancer API Synthesis (Pharmaceutical Manufacturing)

Pharmaceutical manufacturers use flavopiridol as a core molecule in the large-scale synthesis of investigational and approved anticancer active pharmaceutical ingredients (APIs). Its primary function involves acting as a cyclin-dependent kinase inhibitor precursor in targeted cancer therapy development lines. Operations require tight process and documentation controls to align with preclinical and clinical batch validation, where flavopiridol is incorporated during the late-stage synthetic steps prior to final API crystallization, purification, and analytical release.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice (GMP) for Active Pharmaceutical Ingredients
• US FDA 21 CFR Part 210/211
• EU EudraLex Volume 4
• ISO 9001:2015 for pharmaceutical quality systems

Typical usage ratio

• Ranges from 5% to 25% of the total reaction mass, depending on the synthetic route and target API lot size; adjusted according to validated process yields and conversion rates in cGMP production.

Downstream process integration

• Introduced at the core condensation or cyclization stage in the multistep pharmaceutical synthesis line, followed by solvent exchanges, intermediate purification, and re-crystallization under controlled conditions.

Final product types

• CDK inhibitor APIs for oral or intravenous oncology drugs
• Investigational anti-leukemia or anti-lymphoma drug substances
• Reference standards for clinical research programs
• GMP bulk APIs for finished dosage formulation

2. Oncology Injectable Formulation Manufacturing

Sterile injectable drug manufacturers apply flavopiridol as a pharmacopeial-grade bulk substance in oncology formulation units. The compound is solubilized, filter-sterilized, and filled in ampoules or vials under aseptic conditions. It is critical to comply with regional pharmacopoeial standards and to maintain batch traceability throughout fill-finish operations, including fill volume calibration, sterilization parameters, and stability studies.

Industry compliance standards

• USP-NF, European Pharmacopoeia (Ph. Eur.) injectable drug monographs
• WHO GMP for Sterile Pharmaceutical Products
• US FDA 21 CFR Part 212 (PET Drugs) and Part 211 (Finished Pharmaceuticals)
• ISO 14644 cleanroom requirements

Typical usage ratio

• Typically ≤0.5 mg/mL in the finished diluted injectable solution; concentration optimized based on clinical dosage requirements and pharmacopeial assay limits.

Downstream process integration

• Dissolved in sterile water or approved buffer, filtered through 0.22μm filters, introduced to aseptic filling lines, and sealed in single- or multi-dose formats, then labelled and released after QC testing for content and sterility.

Final product types

• Oncology injectable drug vials and ampoules for hospital use
• Clinical trial investigational products (INJ) for cytostatic therapy
• Sterile bulk drug substances for compounding pharmacies
• Pre-filled syringes for cancer therapy trials

3. Analytical Standards & Reference Materials Production

Flavopiridol serves as a reference standard in analytical laboratory and QC settings for pharmaceutical development. Standard producers use highly pure flavopiridol to prepare calibration, control, and proficiency testing materials. These standards are essential for batch release, impurity profiling, and method validation studies in industrial labs globally.

Industry compliance standards

• ISO 17034:2016 Reference Material Producers
• ISO/IEC 17025:2017 Testing and Calibration Laboratories
• USP Reference Standard protocols
• Pharmaceutical company internal SOPs

Typical usage ratio

• Prepared as 0.01-1.0 mg/mL working standard solutions or as neat reference powders; concentration depends on analytical methodology and instrument sensitivity.

Downstream process integration

• Weighing and dissolving in analytical-grade solvents, diluting to standard concentrations, aliquoting, and dispensing into vials or ampoules with certificate of analysis (CoA) for industrial labs and pharma QC teams.

Final product types

• System suitability standards for HPLC, LC-MS
• Qualified reference materials for regulatory filings
• Calibration standards for bioanalytical method validation
• QC positive controls for API identification assays

4. Cytotoxic Compound Library Manufacturing (Discovery & Screening)

Flavopiridol forms part of high-throughput cytotoxic compound libraries supplied to pharmaceutical and academic screening facilities. Library producers require compliant sourcing and homogeneity for downstream robotics-compatible arraying and assay miniaturization. Each batch undergoes stringent identification and purity confirmation before integration into screening sets, where accurate mass and solvent compatibility are mandatory for automation.

Industry compliance standards

• Synthetic Compound Library Quality (ASTM E2709-12)
• Chemical Society screening library guidelines
• GMP-analogous documentation for traceability
• REACH Regulation (EC 1907/2006) for chemical handling in Europe

Typical usage ratio

• Arrayed in 10–100 μM stock solution format, typically 1-2 μL per well in screening plates; adjusted based on miniaturization level and screening protocol.

Downstream process integration

• Distributed into 96 or 384-well microplates, sealed and quality verified for solubility and stability, prior to shipping to HTS (high throughput screening) sites or pharma R&D collaborators.

Final product types

• Cytotoxic oncology screening collections for drug discovery
• Ready-to-use small molecule library panels
• Bioactivity profiling sets for research
• Arrayed validation plates for cell-based assays

5. Pre-Clinical Toxicology Material Manufacturing

Specialized contract organizations and pharma companies source flavopiridol as a toxicology test material under strict GLP and documentation protocols. Material is processed for oral or intravenous administration in animal models, requiring batch-specific certifications and detailed impurity profiling to support IND (Investigational New Drug) filings or regulatory safety dossiers.

Industry compliance standards

• OECD Principles of Good Laboratory Practice (GLP)
• FDA 21 CFR Part 58 (GLP for Nonclinical Studies)
• VICH GLP for veterinary pre-clinical studies
• Supplier audit and lot traceability requirements

Typical usage ratio

• Prepared at animal-dosing concentrations (e.g., 0.1 – 25 mg/kg/day), actual prep concentration based on toxicology protocol and animal weight scaling calculations.

Downstream process integration

• Weighed and dissolved/dispensed into test formulation vehicles, subjected to stability and identity checks, and transferred to in vivo study units per GLP submission batch documentation.

Final product types

• Certified toxicology dosing solutions for rodent and non-rodent models
• Reference toxicants for safety margin calculation
• GLP batch material for regulatory IND submissions
• Archival specimens for long-term toxicological review